Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide, afflicting an estimated 33 million people. 1 In the United States alone, AF-related annual cost estimates are as high as $26 billion.
While some patients experience bothersome symptoms, many remain completely asymptomatic. Most concerning is the severe consequence of untreated AF. Patients with AF are at an increased risk of stroke and systemic embolism, up to 15% per year. 2 In the United States, 800 000
people suffer a stroke annually, and these strokes cause one in every Unsurprisingly, they found less than half (48%) of those surveyed were aware of AF. This differed considerably from the high awareness of heart attacks (74%), stroke (81%), human immunodeficiency/acquired immunodeficiency syndrome (HIV/AIDS; 80%), breast cancer (81%), and prostate cancer (78%). Additionally, they found a striking difference in awareness by country, with Uganda reporting the highest awareness (69%) and Canada the lowest (25%). While differences in the surveyed population and potential selection/responder bias may have contributed to part of the variation, a nearly three-fold difference is hard to ignore.
Perhaps the most important finding from this report is that only 36% of respondents were aware that AF can lead to stroke. With such prominent morbidity and mortality associated with stroke and the presence of a highly effective prevention method (anticoagulation), one would hope that the awareness of this connection was higher.
To help contextualize, the World Health Organization estimates 2.1 million global cases of HIV with one million yearly deaths. To help address a public knowledge gap regarding thrombosis, the
International Society on Thrombosis and Haemostasis began World
Thrombosis Day in 2014. 6 This effort, in partnership with a number of other thrombosis-related organizations, focuses on public awareness of thrombotic disorders, primarily venous thromboembolism and AF.
also highlights the important role of institutions to support educational outreach and clinical decision support. The survey data from
Wendelboe and colleagues would suggest that educational outreach must extend beyond provider education to also include educating the public. To achieve the goal of reduced AF-related stroke burden we must target preventative and therapeutic strategies in addition to awareness.
For example, we must encourage efforts to reduce the development of AF, such as increasing physical activity, weight loss, and treatment of comorbid illnesses (patient and policy levels). The public lexicon should include "AFib" just as easily as it does "heart attack," "stroke," and "cancer." We also need to address issues surrounding medication prescribing, access, adherence, and persistence (patient, provider, institutional, and policy levels). These will require multifaceted efforts to develop, test, implement, and promote care programs. Public health and governmental organizations, pharmaceutical companies, insurers and other payers, professional societies and advocacy organizations, healthcare providers, and patients all must work together to increase the use of stroke-preventative treatment strategies among patients with atrial fibrillation.
Together, we can make important strides in both public awareness of AF and the use of stroke-preventative measures. With regards to public awareness, we now have our starting point. How we reach our ultimate goal remains an exciting and uncharted journey.
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